A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Adverse reactions
- Acronyms MONITOR
- Sponsors Biohaven Pharmaceuticals; Pfizer
- 15 Feb 2024 Planned End Date changed from 24 Jan 2035 to 30 Apr 2034.
- 15 Feb 2024 Planned primary completion date changed from 24 Jan 2035 to 30 Apr 2034.
- 30 Oct 2023 Planned primary completion date changed from 4 Nov 2029 to 24 Jan 2035.